Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.
Aptalis president and chief executive officer Frank Verwiel said the launch of Viokace brings an uncoated pancreatic enzyme to market, providing another important treatment option for adult patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.
"VIOKACE provides Aptalis an opportunity to support this patient population, as well as the healthcare professionals who treat them, in meeting the significant challenges posed by these conditions," Verwiel added.
Viokace, in combination with a proton pump inhibitor, produced significant improvement in fat absorption in the pivotal, placebo-controlled study of patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.